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The androgenic action of dihydrotestosterone (DHT) is an-
tagonized by agents that compete with testosterone for the 
Sa-reductase enzyme and by agents that block the binding of 
DHT to its receptor. The topical synergistic effect of Sa-re-
ductase (SaRI) and androgen receptor inhibitors (ARI) was 
determined by measurement of the sebaceous gland size 
(SGS) of the ventral ear skin of the intact, sexually mature 
male Syrian hamsters. Progesterone (P), a SaRI, and spiro-
nolactone (SL), an ARI, produced a dose responsive decrease 
in SGS at topical concentrations of 0.01 % to 5.0%. At con-
centrations of 1,3, and 5%, P and SL combinations produced 
neither an additive nor synergistic inhibition ofSGS. At very 
low concentrations of up to 0.10%, neither P nor SL alone 
A ntiandrogens are divided into two major classes. The first is represented by Sa-reductase inhibitors (SaRI), which compete with testosterone for the binding site in the Sa-reductase enzyme. The second group is comprised of androgen receptor inhibitors (ARI), 
w hich interfere with the binding of dihydrotestosterone (DHT) to 
the androgen receptor protein . Details of the biochemical and phys-
iologic effects of antiandrogens can be found in numerous reviews 
[e.g. , Refs 1,2). 
Because both types of antiandrogens act through entirely differ-
ent mechanisms, the overall efficacy of antiandrogen therapy might 
be enhanced by using combinations of selected compounds from 
Manuscript received N ovember 3, 1987; accepted for publication April 
2 1,1988. 
Reprint requests to: Jonathan R. Matias, Biomedical Research Station, 
Orentreich Foundation for the Advancement of Scicncc, Inc., RD 2, Box 
375, Cold Spring-on-Hudson, NY 10516. 
Abbreviations: 
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17 PCA: 4-androstcn-3-onc-17 P carboxylic acid 
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DOCA: desoxycorticosterone acetate 
HF: hydroxyfluta111ide 
4MA: 1l,Il-diethyl-4 1l1cthyl-3-oxo-4-aza-Sa-androstanc 17p-carboxa-
111 ide 
MPA: 111edroxyprogcstcronc acetate 
P: Progesterone 
4P3: 4-prcgnene-3-one 
5 RI : Sa-rcductase inhibitor 
SL: spironolactone 
SGS: sebaceous gland size 
produced any effect on SGS. When combinations of these 
two steroids were applied at low concentrations, SGS de-
creased unilaterally to approximately SO%. This synergy oc-
curred best at a P : SL ratio of 1 : 2. The lower effective con-
centrations of P may be explained by its greater percutaneous 
absorption. Synergy was also demonstrated at low concen-
trations with other antiandrogens: cyproterOlle acetate, can-
renone, hydroxyflutamide, and N -N-diethyl-4-methyl-
3-oxo-4-aza-5a-androstane-17,B-carboxamide. The use of 
anti-androgen combinations at low concentrations is of value 
because of the decreased risk of systemic side effects while 
maintaining potent topical efficacy. ] Jil l/est Dermatol 
91:429-433,1988. 
each class. In this study the androgen-sensitive sebaceous glands of 
the hamster ventral ear pinna were utilized as a target organ for 
evaluating the effect of topically applied combinations of antian-
drogens. W e report here that combinations of topical ly applied 
SaRI and ARI exert a potent synergistic effect at very low doses 
without evidence of systemic side effects. 
MATERIALS AND METHODS 
Animals Male Syrian golden hamsters were purchased from Har-
lan-Sprague Dawley, Inc. (Farmersburg, IN) , at 10-11 weeks of 
age. The animals werc houscd at a density of 4 to 5 animals per cage 
with a photoperiod of 14 h light and 10 h dark. Food and water were 
provided ad libitum. The hamsters were acclimated to the labora-
tory conditions for at least 1 week prior to the experiments. 
Chemicals The following were purchased commercially: spiron-
olactone (SL) from Sigma C hemical Company (St. Louis, MO); 
progesterone (P) from Upjohn Company (Kalamazoo, MI) ; 4-preg-
ncne-3-one (4P3) fro m SyntBiotech, Inc. (Ncw York, NY); desox-
ycorticosterone acetate (DOCA) , medroxyprogesterone acetate 
(MPA) and 4-androsten-3-one-17p-carboxylic acid (1 7BCA) fro m 
Steraloids (Wil ton, NH). The following compounds were received 
as gifts: canrenone (C N) from G.D. Searle Company (Skokie, IL); 
n,n dicthyl-4 methyl-3-oxo-4-aza-Sa-androstanc 17p-carboxa-
lI1ide (4-MA) from Merck, Sharpe, and Dohme (Rahway, NJ) ; hy-
droxyflutamide (HF) and cyproterone acctatc (CA) from Schering 
AG (Berlin, West Germany) . 
Radiolabeled steroids were obtained from the following sources: 
[1,2-3H(N))-progesterone (S.A. 57.5 CI/l11mol) from New En-
gland Nuclea r (Boston , MA); [1 ,2-3H (N))-spironolactone (S.A. 44 
Ci/ mmol) fro m Amersham (Arlington Heights, IL). 
Procedures for the Topical Study The antiandrogens were dis-
solved in acctone either separately or in combinations. Twenty-five 
0022-202X/88/S03. 50 Copyright © 1988 by The Society for Investiga tive Dcrmatology, Inc. 
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microliters of each solution was applied with a micropipette on the 
ventral surface of the right ear pinna, once in the morning and once 
in the afternoon of each day, Monday through Friday. The left 
pinna of the same animal was not treated and served as an indicator 
of any systemic effect of the antiandrogen treatment. Control ani-
mals received topical applications of acetone alone to the right 
pinna. Unless otherwise specified, the treatments were terminated 
after 4 weeks and the animals were killed by cervical dislocation. A 
preliminary study indicated that chis was the minimum time for 
attaining an antiandrogenic response in intact mature males. 
The method used for evaluating the sebaceous gland response was 
previously described in detail (3,4]. Briefly, the ear was cut at the 
proximal base with scissors, and the ventral ear skin, rich in seba-
ceous glands, was manual ly separated from the carti lage. The skin 
was immediately stained for 3h with 0.1 % (w Iv) solution of Sudan 
Black B in propylene glycol. The ear skin was then fixed in 10% 
buffered formalin after an overnight rinse in a solution of propylene 
glycol:water (85:15). A 2-mm punch biopsy of the medial zone (an 
area 5-8 mm from the apex of the pinna along the midline) was 
obtained. 
The whole-mount preparation of the ventral pinna was viewed 
from the dermal side at a magnification of 150X using an Ortholux 
II microscope equipped with a drawing attachment (Leitz). The size 
of each sebaceous gland unit was quantitated planimetrically using a 
computerized graphics calculator (Numonics Corp., Lansdale, PA). 
Procedure for the Evaluation of Percutaneous Absorption 
The penetration rate of P and SL through the skin was determined 
by measuring the urinary excretion of each steroid according to the 
method of Feldmann and Maibach [5] . The radiolabeled steroid (0.5 
.uCi) was dissolved in acetone with 4 .ug of unlabeled carrier, in a 
total volume of 10.u1. After applying the solution on the ventral ear 
pinna, the hamster was placed inside a plastic metabolic cage (Nal-
gene) . Urine was collected daily for 5 d. An aliquot of urine was 
counted in a scintillation counter (Packard TriCarb) using 3H-tolu-
ene as the internal standard. The values were corrected for incom-
plete urinary excretion as described previously [5]. 
Calculation of the Index of Synergism or Antagonism To 
determine whether or not a synergistic, antagonistic, or additive 
effect was present for each combination, an index was calculated as 
follows: lndex = (1 - D/c)/(1 - Alc) + (1 - Blc), where A is 
the mean value calculated for SaRI treated hamsters; B is the mean 
value calculated for ARI treated hamsters; C is the mean value 
calculated for the vehicle treated controls for each treatment group; 
D is the mean value calculated for the SaRI and ARI combination. 
A purely additive effect is represented by an index of 1. An' index 
greater than 1 shows a clear synergistic activity, while an index 
lower than 1 demonstrates a competitive effect. 
Statistics The student's t-test (two tailed) was used to evaluate the 
significance of all experimental data. 
RESULTS 
The effects of various topical doses of p and S L on the male hamster 
ear sebaceous glands are shown in Fig 1. P produced a 60% reduc-
tion in sebaceous gland size at the highest concentration used (5%), 
without statistically significant systemic effects 011 the contralateral 
untreated ear. In contrast, only a modest reduction of sebaceous 
gland size was observed with SL. A maximum inhibitory effect of 
approximately 30% was observed at the 5% concentration of SL. 
This effect was accompanied by a marked systemic effect as evi-
denced by the decrease in size of sebaceous glands in the contralat-
eral untreated ear skin. 
Combinations of P and SL were applied topically at concentra-
tions of 1 %, 3%, and 5%. The data in Table I show that the seba-
ceous gland size was not significantly different compared to the 
application of P or SL separately. Calcu lations of the index showed 
that combinations of P or SL produced competitive effects when 
applied topically at high concentrations. 
When applied alone, P or SL produced little direct inhibition at 
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Figure 1. Dose-dependent inhibitory effect of P and SL on the sebaceous 
glands of male Syrian hamsters (N=5-6 animals per data point). (e): 
treated;(o): contralateral untreated. 
low doses, i.e., doses of 0.1 % or lower. However, a marked syner, 
gistic inhibition, particularly at the lowest dose (Exp. B, Table II), 
was evident when P and SL were combined. When applied togethet 
at a concentration of 0.025% for P and 0.05% for SL, the sebaceous 
gland size decreased to 58% of the control value. It is also important 
to note that the systemic side effects did not occur at such lo\\> 
concentrations (see Fig 1). This experiment was repeated two mor~ 
times and showed the same synergistic antiandrogenic effect. Fur, 
therdi lution of the 0.025% P and 0.05% SL combination resulted ill. 
eventual loss of the antiandrogenic effect (Table III). 
Different ratios of P and SL combinations at low concentrations 
were also tested to determine the combination that would produce 
the optimal synergistic effect. As can be seen in Fig 2, synergisnl 
occurred best at a P:SL ratio of 1:2. To test whether this ratio was 
related to the penetration rates of these steroids through the skin, 
radiolabeled P and SL were applied to the ventral ear skin and the 
rate of percutaneous absorption was measured . The data (Table IV) 
indicated that P was absorbed at twice the rate observed for SL. 
Synergistic effects were also demonstrated for other potent 
SaRI's, such as 4MA and 4P3, when used in combination with SL 
(Table V, experiments A and B). Conversely, similar effects were 
noted when other potent ARI's (CA, HF, and CN) were combined 
with P (Table V, experiments C, D, and E). As ill previous experi-
ments, the antiandrogenic action seen with these drugs at low topi-
cal doses occurred without evidence of systemic effects (data not 
shown). In contrast, combinations of two SaRI's (P and 4MA) or 
Table I. Effect of the Topical Application of Combinations of 
P and SL at High Concentrations (1, 3, and 5%) on Sebaceous 
Gland Size in Adult Male Syrian Golden Hamsters 
(Mean ± S.E. of Five Animals per Group) 
Sebaceous Gland Size 
Treatment (mm2 X 10- 3) % Control Index 
Control 36.9 ± 3.3 100.0 
1% P 22.2 ± 1.) 60.5 
1% SL 23.9 ± 0.9 64.8 
1 % P + 1% SL 24.1 ± 0.9' 65.3 0.46 
3% P 18.9 ± 1.5 51.2 
3% SL 21.6 ± 1.2 58.5 
3% P + 3% SL 18.4 ± 0.8b 49 .9 0.55 
5% P 17.9 ± 2.0 48.5 
5% SL 19.1 ± 1.3 51.8 
5% P +5% SL 18.1 ± 0.8b 49.1 0.51 
• Statistically significant compared with the cOlltro\ (P < 0.01). but 1I0t significant 
compared with either P or SL alone. 
b Statistically significa nt compared with the control (P < 0.001). but not significant 
compared with either P or SL alone. 
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Table II. Effect of the Topical Application of Low Concentrations of P and SL Combinations on Sebaceous Glands in Adult Male 
Syrian Golden H amsters (Mean ± S.E) 
Experimental Sebaceous Gland Size 
Treatment (N) (mm2 X 10- 3) % Control Group Index 
A Control (7) 34.0 ± 1.9 100.0 
0.05% P (7) 30.5 ± 1.9 89.7 
0.10% SL (6) 30.4 ± 1.8 88.4 
0.05% P + 0.10% SL (5) 23.9 ± 0.9' 70.3 1.36 
B Control (5) 31.9 ± 1.5 100.0 
0.025 % P (5) 30.2 ± 1.7 94.7 
0.05% SL (5) 28.1 ± 2.4 88.1 
0.025% P + 0.05% SL (5) 18.6± 2. 1h 58.3 2.42 
, P < 0.001 compared with the cO lltrol; P < 0.01 compared with either P or SL. 
b P < 0.001 compared with the control; P < 0.001 compared with either P or SL. 
Table III. The Effect of Further Di lution of 0.025% P and 0.05% SL Topical Preparation Oil the Antiandrogenic Effect on the 
Sebaceous G lands of Adult Male Syrian H amsters (Mea n ± S.E) 
Sebaceous Gland Size 
Treatment (N) 
Control (7) 
0.025% P + 0.05% SL (5) 
0.012% P + 0.025% SL (6) 
0.006% p + 0.01 2% SL (6) 
, NS: Not Significant at the 0.05 level of probability. 
Table IV. In Vivo Percutaneous Absorption Rate of P and SL 
through the Ventral Ear Skin of Male Syrian Golden Hamsters 
(Mean ± S.E) 
Absorption 
Experiment (N) (% of Dose Applied) P 
Progesterone 4 73.5 ± 5.7 
< 0.01 Spironolactone 4 40.3 ± 5.4 
two ARI (CA and SL) did not produce any synergistic inhibitory 
effects on the hamster ear sebaceous glands (Table VI). 
Increasing the number of 5a-RI and ARI in a single topical prepa-
ration was also ineffective in increasing th e magnitude of the an-
tiandrogenic effect (Table VII). This "antiandrogen cocktail" pro-
duced an approximately 55% decrease in sebaceous g land size. 
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Figure 2. Determination of the ratio of P and SL required to produce the 
optimum synergistic antiandrogenic effect on hamster sebaceous glands. 
Each data point represents an experiment consisting of four groups of five 
hamsters treated with various combinations of P and SL. The index of 
synergism or antagonism was calculated for each experimental set. Note that 
the concentration of each steroid in any combination was at 0.1 % or lower. 
(mm2 X 10- 3) % Control p 
30.0 ± 1.4 100 
16.9 ± 0.6 56 .3 0.001 
18.5 ± 1.1 61.7 0.001 
25.5 ± 2.1 85.0 NS' 
However, this inhibitory effect was similar to that produced by the 
combination of 0 .025% P and 0.05% SL. Despite the increased 
number of antiandrogens present at low concentrations, the effect 
remained local ized on the treated ear. 
As noted above, a preliminary study indicated that any topical 
application of P or SL for a duration of less than 4 weeks was 
insufficient to produce a reduction of sebaceous gland size in normal 
male h amsters . For this reason , topical therapy was given for a 
Table V. The Effect of Various Combinations of SaRI and 
ARIon H amster Ear Sebaceous Glands (Mean ± S.E) 
Area of 
Experimental Sebaceous Glands 
. Group Treatment (N) (mm2 X 10- 3) % Control Index 
A Control (6) 37.3 ± 1.1 100.0 
0.025% 4MA (6) 34.5 ± 2.2 92.5 
0.050% SL (6) 38.4 ± 1.7 102.9 
4 MA +SL (6) 23.1 ± 1.5' 61.9 3.66 
B Control (5) 31.3 ± 2.0 100.0 
0.05% 4P3 (5) 26 .7 ± 1.0 85.3 
0.10% SL (5) 26.1 ± 0.7 83 .0 
4P3 + SL (5) 18.5 ± 0.6b 59.1 1.29 
C Control (7) 34.0 ± 1.9 100.0 
0.05% P (7) 30.5 ± 1.8 89 .7 
0.10% CA (6) 31.7 ± 1.9 93.2 
P+CA (6) 22.5 ± l.4c 66 .2 1.98 
D Control (7) 30.0 ± 1.4 100.0 
0.05% P (6) 30.5 ± 1.0 101.7 
0.10% HF (6) 24.4 ± 0.9 81.0 
P+ HF (5) 20.3 ± 1.2d 67.7 1.87 
E Control (6) 31.8 ± 1.6 100.0 
0.025% P (5) 30.2 ± 1.5 95.0 
0.05% CN (5) 29.7 ± 1.3 93.4 
P +CN (5) 17.5±1.1e 55.0 3.88 
• P, 0.001 compared with the control; P < 0.005 compared with 4MA alone or SL 
alone. 
h P < 0.001 compared with either control, 41'3, or SL. 
, P < 0.001 compared with the control; P < 0.01 compared with P or CA alone. 
d p < 0.001 compared with the control and P alone; I' < 0.05 compared with HF 
alone. 
, p < 0.001 compared with either control, P alone, or Cn alone. 
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Table VI. Absence of Synergistic Antiandrogenic Activity with 
CQmbinatiQns of Two. ARI Qr Two. SaRI Qn the Hamster Ear 
Sebaceous Glands (Mean ± S.E) 
Experimental 
Group 
A 
B 
Treatment 
Control 
0. 1% SL 
0.1% CA 
SL+ CA 
Contro l 
0.05% P 
0.05% 4MA 
P+4MA 
(N) 
(7) 
(6) 
(6) 
(7) 
(6) 
(6) 
(6) 
(6) 
Sebaceous Gland Size 
(mm2 X 10- 3) % Control 
34.0 ± 1.9 100.0 
30.4 ± 2.0 89.4 
31.7 ± 1.9 93.2 
28.5 ± 1.5' 83.8 
28.6 ± 1.5 100.0 
28.7 ± 2.1 100.4 
28.2 ± 2.0 98.6 
26 .8 ± 0.6h 93.7 
• Significant at < 0.05 compared with the control; not significant COtnpared wi th 
0. 1 % SL or 0. 1 % CA. 
b Not significant compared with the control , 0.05% P, or 0.05% 4MA. 
duration Qf 1 month in the abQve studies. HQwever, the effect Qf 
tQpical applicatiQns fQr IQnger p.eriQds was a lso. evaluated . Figure 3 
shQ:Ws that the effect did nQt Increase With longer dUrations Qf 
tQPlcal therapy. HQwever, it is important to nQte Qnce agai n that the 
anti-androgenic effect Qf cQmbinatiQn th erapy remained lQcalized 
to. the treated ear even after 3 mQnths Qf tQpical applicatiQll (data nQt 
shQwn). 
DISCUSSION 
Central to. th e ~tio l Qgy Qf various androgen ic dermatoses affiicting 
human bemgs IS the penpheral cQnversion Qf circulating testoster-
one to dlhydrQtestosterone (DHT) and the fQrmation of a DHT -re-
ceptor complex. Provided that there is an absence of otber endo-
crinopathies, current mQdes Qf therapy involve ,the use Qf systemic 
and/Qr topical antiandrogens. NumerQus rapers have already been 
published that demQnstrate the efficacy 0. oral CA [e:g., 6,7], and 
more recently, oral SL [8,9J. Because commQn acne, lurSlltism, and 
male pattern baldness are cQnsidered essentia!ly cosm~tic problems 
not worthy Qf an unfavQrable n sk: benefi t ratIO, there IS an obviQUS 
~eed to. develQP PQtent, locally effective treatment th at avoids the 
Side effects attendant .to systemic a.ntiandroge~ therapy [10,11). 
.~ecause Sa-:eductlon and sterOId-receptor interactIOns are each 
cflncal events III the expression of androgen action, it is theQreti-
cally possible ~o use inhibitQrs Qf each pathway in cQlllbinatiQn. 
TIllS hYPQthesls was tested by appl ying cQmbinations of these CQm-
PQunds Qn the hamster ventral ear skin and thrQugh the assess ment 
Qf the antiandrogeni c effect by measurement Qf the sebaceQus 
glands. The suitability of this cutaneous model [1 2) and the useful-
ness of the methQd used fQr measurement have been discussed in 
detail in previous reports [3,4]. 
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Figure 3. Effect of longer duration of treatment on the antiandrogenic 
effect of the combination of 0.05% P and 0.1 % SL (N=5-6 animals per 
group) . 
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Table VII. Effect Qf th e Simultaneous AdministratiQn of Five 
Different Sa-Reductase Inhibitors and Five Androgen Receptor 
Inhibitors Qll Sebaceous G land GrQwth 
Treatment' 
Control Vehicle 
Antiandrogcn Combination 
a) trea ted side 
b) untreated side 
(N) 
(5) 
(6) 
Sebaceous Gland Size 
(mm2 X 10- 3) 
. 31.2 ± 2.3 
14.1±0.7 
28.6 ± 1.0 
ph 
.001 
NSb 
'The SaRI consist of DOCA, MPA, P, 17BCA, and 4P3; ARI consists of CA, RlJ 
2956, O HF, SL, and CN . 
• Values were compared with the control vehicle. N S: Not Significant atO.05 Ieve! of 
probability . 
P was selected as a representative SaRI because it has been shown 
to. be a potent naturall y Qccurring inhibitQr of the Sa reductase 
enzym e l13,14J. SL, an aldosterQne antagQnist currently used in the 
trea tment of essential hypertension, exerts its antiandroge nic effect 
through a) impairment in tes tQsterQne biosynthesis via reductiQn Qf 
17[3 -hydroxylase activity and reductiQn of cytochrQme P4S0 COll-
tent and b) competitive inhibition Qf DHT binding to the cytoplas-
mic andrQgen receptQr protein [15]. These steroids were considered 
ideal candidates for the experiments because both had preVIOusly 
been demonstrated to. decrease sebaceous glands size in the male 
hamster ear when applied topicall y [4] . 
Data presented in this paper demQnstrate cQnclusively that such 
combinatiQns can exert a synergistic inhibitQry effect on the seba-
ceous glands of adult sexually mature Syrian hamsters. The syner-
gism, additivism, and antagQnism of antiandrQgen combinatiQns 
were also examined using th e methQd described by Berenbaum [1 6] 
and found to. be in agreem ent with Qur own calcu lations. MQre 
important, the synergy of these two. classes of inhibitors occurred 
only at very low topical dosages. For example, the magnitude of 
sebaceQus gland reduct iQn induced by a combinatiQn of 0.025% P 
and O.OS % SL (Table II) was equivalent to the separate applicatiQns 
of 1 % P Qr 3% SL. Because the cQmbinations are efficaciQus at lQW 
doses, the possibility of systemic side effects are, therefQre, greatly 
minimized. 
Why synergism was evident at lQW but not at high tQpical doses 
remains puzzling. The present data cannot explain this phenome-
nQn . However, an insight into this question may be found when the 
percutaneous absorption rate (P AR) Qf sterQids is considered. In the 
case Qf glucocQrticoids, fQr exampl e, Stoughton [17] has shown that 
increasing th e concentratiQn Qf steroid in the topica l preparation 
causes a decline in the PAR and a proportionate reduction in its 
cutaneous biQlogic effect. When tes tQsterone 17 [3-valerate was ap-
plied topically, 0 .04% concentratiQn was fQund to. be as active as 
0.2% or 1.0% in prQd ucing cutaneous vasoconstriction . Although 
satisfactory explanations for this phenomenQn are still lacking, 
these observations may be similar in mechanism to. th e low dose 
effects seen in this repQrt. One must also consider th e possibility that 
the SaRl and ARI in the sQlutiQn may interact pharmacolQgically in 
some still unknown manner to create an antagonism at high con-
centratiQns and synergism at lower cQncentratiQns. 
A P:SL ratio of 1:2 was found to be optimal fQr inducing the 
inhibitory effect . An alysis of the percutaneQus absorptiQn of these 
steroids revealed that P penetrates through the epidermal barrier at 
twice the amou nt Qbserved for SL. The apQlar nature of P allows it 
to penetrate the skin more readily than SL so that a proPQrtionately 
sma ll er amount of P is required to be present in the formulatiQn. 
It is clear frQm the data that the cQncept of cQmbination antian-
drogen therapy also applies to other PQtent antiandrogens prQvided 
that th e combination consists of compounds from each class of 
antiandrogens. 4P3, an ethyl analogue of P, inhibits the growth of 
sebaceous glands as effectively as the parent compound (unpub-
lished data), and act in synergy with SL at low doses. A si milar 
relationship was observed between SL and 4-MA, an a'Za steroid, 
which is known to ac t as a potent inhibitor of tl]e Sa-reductase 
enzy me [18] . In converse, knQwn ARl's, such as CA, HF [19J , and 
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CN [20], produced synergistic inhibition when combined with P. 
However, combinations 'of two ARI's or two SaRI did not act 
synergistically on the hamster ear skin sebaceous glands. 
The combined use of various drugs for the treatment of acne has 
been described previously. Marsden et al [21] administered isotre-
tinoin and CA systemically in patients with acne and found the 
absence of synergy between the two compounds, although each one 
reduced sebum production via independent mechanisms. Estrogens 
also reduce sebum production through local [22] inhibition of seba-
ceous activity and through inhibition of testosterone production via 
the pituitary-gonadal axis [23,24]. Systemic administration of estro-
gens with CA [25] or glucocorticoids [26] failed to demonstrate any 
synergistic antiandrogenic effect. The lack of synergy may in part be 
due to the dose chosen for the studies or that insufficient levels of 
these compounds actually reach the target tissue . In a recent study, 
we have shown that a combination of Sa-RI and ARI was ineffec-
tive in inhibiting the growth of experimental prostate adenocarci-
noma, normal prostate, and seminal vesicle in a synergistic manner 
[27]. One may also consider the possibility that synergism may be 
best achieved only through direct administration of inhibitory com-
pounds to the target site, preferably via topical administration. 
To our knowledge, the concept of topical use of SaRI and ARI 
combinations have not yet been tested clinically. The present find-
ings using this cutaneous model strongly suggest that this concept 
may have a potential therapeutic benefit in the local treatment of 
androgenic dermatoses because of its potent direct action at very safe 
drug concentrations. 
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